Contact us


A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy

The purpose of the study is to compare survival of patients who receive chemotherapy and ramucirumab vs. chemotherapy alone as second line treatment for non-small cell lung cancer after prior first line platinum based chemotherapy.

For more information, please visit

Patient Population Investigational Product(s) Phase Status
Non Small Cell Lung Cancer Ramucirumab III Closed